Abstract 647P
Background
Colorectal cancer (CRC) results from the combination of genetic alterations and environmental risk factors. Several evidences indicate that the diet may have a role in prevention and progression of CRC, but more research is needed to clarify the heterogeneity of dietary associations with CRC.
Methods
Patient-derived xenografts (PDXs) were generated implanting subcutaneously human CRCs at different staging into immunodeficient mice, and feeding with control normal diet (ND) and classical western diet (WD). Tumor phenotype, transcriptomic, genetic and metabolomic were analyzed.
Results
The response to WD was heterogeneous among all generated PDXs. Only one out of three showed a greater growth in mice fed with WD. Particularly, WD induced transcriptomic perturbations of several genes related to epigenetic regulations and tumor progression, remodeling tumor microenvironment, promoting mucin secretion, mitochondria dysfunction and metabolic reprogramming. Interestingly, the three PDXs responded to the same WD with a distinct metabolomic profile that was validated through the machine learning. With whole exome sequencing, PDXs did not share the same somatic cancer mutations that could play a key role in conditioning response to a specific diet. Consistently, the same heterogeneous response to WD in tumor growth was observed in xenografts generated with CRC cell lines. To strictly mimics human diet, we tested in comparison to classic WD, humanized WD diet that displayed a different tumor behavior. The analysis of patient derived organoids developed from PDX fed with humanized diets revealed that the altered metabolic reprogramming acquired in vivo is also maintained in vitro in absence of any stimulus, suggesting a metabolic memory of cancer cells.
Conclusions
Specific CRC somatic mutations, modifying several signaling pathway and tumor metabolism promote tumor growth and progression, and could be predictive of a response to a specific diet. In this scenario, PDX could be considered as a suitable approach to study the response to the diet and to provide a screening of different diets in order to create a dietary guidance for CRC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Humanitas University.
Funding
PRIN.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
649P - The genomic landscape of appendiceal adenocarcinoma (AA) revealed by 855 whole exome sequences (WES)
Presenter: Michael White
Session: Poster session 11
650P - Genomic profiling of small bowel adenocarcinoma: A pooled analysis
Presenter: Thomas Aparicio
Session: Poster session 11
651P - DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: A multicenter propensity score matching study
Presenter: Christophe Borg
Session: Poster session 11
726P - Circulating cell-free DNA-based biomarkers as a new tool for prognosis and surveillance of adrenocortical carcinoma
Presenter: Cristina Ronchi
Session: Poster session 11
727P - Clinical outcome of anlotinib (A) and tislelizumab (T) in metastatic adrenocortical carcinoma(mACC): A one-arm single-center experience
Presenter: HAO LI
Session: Poster session 11
728P - Brain metastases in advanced thyroid carcinoma: Clinical and molecular characteristics and outcomes
Presenter: Thais Megid
Session: Poster session 11
729P - Prognostic significance of nodal micrometastases in patients with non-functioning pancreatic neuroendocrine tumors (NF-PanNETs): A survival analysis from a prospective observational study
Presenter: Valentina Andreasi
Session: Poster session 11
730P - The outcome of combine radioligand and CAPTEM therapy in patients with advanced, unresectable, progressive GEP-NET
Presenter: Jaroslaw Cwikla
Session: Poster session 11
748P - Outcomes for patients (pts) with advanced endometrial cancer (aEC) who completed pembrolizumab (pembro) and continued lenvatinib (LEN) in the phase III Study 309/KEYNOTE-775
Presenter: Emeline Colombo
Session: Poster session 11